|
|
Hana Biosciences, Inc. - Comparative Business Analysis Snapshot
Business Description
Hana Biosciences, Inc.. The Group's principle activity is to acquire, develop and commercialize of innovative biopharmaceutical products to advance cancer care. It has four product candidates in various stages of development: Marqibo being developed for the treatment of adult acute lymphoblastic leukemia (ALL) and metastatic uveal melanoma. Menadione, a novel supportive care product candidate being developed for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors (EGFRI), a type of anti-cancer agent used in the treatment of certain cancers. Brakiva developed for the treatment of solid tumors including small cell lung cancer and ovarian cancer. Alocrest developed for the treatment of solid tumors such as non-small-cell lung cancer (NSCLC).
Competitor Analysis
This analysis compares Hana Biosciences, Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
